CytoDyn Inc.
No SEC Form 4 filings for $CYDY in the last 30 days.
See all $CYDY insider activity →Robert E. Hoffman, 60, has been named CEO of CytoDyn, replacing Jacob P. Lalezari, who will now lead research and translational sciences. Hoffman has held CFO/CEO roles at other biotech firms and serves on boards. He joined CytoDyn as CFO in May 2025.
CytoDyn Inc. (CYDY) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Exhibit 99.1 CytoDyn Appoints Robert E. Hoffman as Chief Executive Officer Dr. Jacob Lalezari to remain with Company in scientific innovation and discovery role VANCOUVER, Washington, October 19, 2026 -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a clinical-stage on
CytoDyn Inc. (CYDY) will host an investor webcast on October 19, 2026, to discuss clinical and financial updates, including early tumor-DNA observations from its CLOVER cancer study. The event will feature CytoDyn executives and a Natera representative, focusing on their strategic collaboration. The webcast will be available for replay for 30 days.
Over the past 7 days, AlphAI's AI scored 7 news stories mentioning CYDY (CytoDyn Inc.). Coverage has skewed bearish: 0 bullish, 6 neutral, and 1 bearish.
Recent CYDY coverage spans financial news, earnings and corporate actions.
Leadership transition may affect strategic direction and investor sentiment.
Leadership transition may create short‑term volatility as investors reassess execution outlook.
The webcast is informational with no new clinical data disclosed, so limited immediate market impact.
The larger-than-expected loss and lack of revenue suggest heightened cash‑burn risk, likely pressuring the stock lower.
The loss and going‑concern warning are likely to pressure the stock lower.
AlphAI scores every news story that mentions CYDY with an AI model for sentiment and relevance, and aggregates insider trades from CytoDyn Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Robert E. Hoffman, 60, has been named CEO of CytoDyn, replacing Jacob P. Lalezari, who will now lead research and translational sciences. Hoffman has held CFO/CEO roles at other biotech firms and serves on boards. He joined CytoDyn as CFO in May 2025.
1 min readCytoDyn Inc. (CYDY) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Exhibit 99.1 CytoDyn Appoints Robert E. Hoffman as Chief Executive Officer Dr. Jacob Lalezari to remain with Company in scientific innovation and discovery role VANCOUVER, Washington, October 19, 2026 -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a clinical-stage on
2 min readCytoDyn Inc. (CYDY) will host an investor webcast on October 19, 2026, to discuss clinical and financial updates, including early tumor-DNA observations from its CLOVER cancer study. The event will feature CytoDyn executives and a Natera representative, focusing on their strategic collaboration. The webcast will be available for replay for 30 days.
1 min readCytoDyn Inc. reported a net loss of $19.9M for Q3 2026, widening from a $5.5M loss in the prior-year quarter, with no revenue disclosed. Diluted EPS was $(0.01). The company is focusing on leronlimab's clinical development in oncology, increasing R&D spending, and seeking partnerships for financing.
1 min readCytoDyn Inc. reported a net loss of $42.7M for fiscal 2026, a significant decline from a $3.7M net income in 2025. The company's cash reserves stood at $11.9M, with working capital and accumulated deficits raising concerns about its ability to continue operations. CytoDyn cited clinical development progress and strategic partnerships as key highlights.
1 min readWe have a $2.75 Price Target on CytoDyn ( CYDY ) in the Next 6 to 12 Months. The stock's current price is around $0.32. CytoDyn Inc. is a clinical-stage biotechnology company focused on developing leronlimab, a monoclonal antibody targeting the CCR5 receptor, with applications in HIV, ...
4 min read
